Zepbound

Pharma

BMO says Lilly is pulling ahead of Novo in obesity market battle

Eli Lilly has caught up to Novo Nordisk, says BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indiana company.

Kevin Dunleavy Apr 17, 2025 4:30pm

Lilly files lawsuit against spa for selling repackaged Zepbound

Apr 7, 2025 5:00am

In another banner year for Lilly, CEO David Ricks nets $29.2M

Mar 10, 2025 9:15am

A gavel in the foreground with the scale of justice in the background

Compounders forced to stop making Lilly weight-loss copycats

Mar 7, 2025 8:50am

Lilly swells manufacturing outlay to more than $50B since 2020

Feb 26, 2025 9:30am

Eli Lilly makes Zepbound vials cheaper for self-paying patients

Feb 25, 2025 11:35am